Emma Walmsley, GSK CEO, joins CNBC's 'Squawk on the Street' to discuss the company's most recent earnings, innovation ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

GSK PLC GSK shares rose 4.69% to £14.63 Wednesday, on what proved to be an all-around favorable trading session for the stock ...

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage ...

British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

GSK ( NYSE: GSK) CEO Emma Walmsley said on Wednesday that her company is in discussions with the Trump administration on how ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

Its second-quarter sales rose to 7.99 billion pounds from 7.88 billion pounds in the same period the year prior.

GSK anticipates high sales and profit growth in 2025 after surpassing second-quarter forecasts, while addressing U.S. tariffs ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s cobolimab has ...

British pharmaceutical group GlaxoSmithKline said Wednesday that its annual performance should be better than expected, ...